Tags

Type your tag names separated by a space and hit enter

Prospective study of plasma enterolactone and prostate cancer risk (Sweden).
Cancer Causes Control. 2004 Dec; 15(10):1095-102.CC

Abstract

OBJECTIVES

Enterolactone, a phytoestrogen produced by the intestinal microflora from precursors in plant foods, has been postulated to protect against hormone-dependent cancers. We studied the association between plasma enterolactone and risk of prostate cancer.

METHODS

In the Northern Sweden Health and Disease Cohort, enterolactone concentrations were measured by time-resolved fluoroimmunoassay in plasma taken from 265 men who were diagnosed with prostate cancer at a mean time of 5 years after blood collection, and in plasma from 525 control men, matched for age and date of blood collection.

RESULTS

There was no significant association between quartiles of plasma enterolactone and risk of prostate cancer. Odds ratios for prostate cancer, estimated by conditional logistic regression for increasing concentrations of enterolactone in quartiles were 1.00 (referent), 0.81 (95% confidence interval 0.52-1.27), 1.03 (0.67-1.58), and 1.22 (0.80-1.86). Adjustments for body mass index (BMI), smoking status and stratification for age, lag time, storage time and tumour characteristics did not materially alter risk estimates. Men with very low enterolactone levels, however, had significantly higher risk of prostate cancer, odds ratio for bottom decile versus all other deciles was 1.68 (1.03-2.74).

CONCLUSIONS

Our results do not support the hypothesis that enterolactone formed from dietary lignans protects against prostate cancer.

Authors+Show Affiliations

Department of Surgery and Perioperative Sciences, Urology and Andrology, Umed University Hospital, Sweden. par.stattin@urologi.umu.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15801493

Citation

Stattin, Pär, et al. "Prospective Study of Plasma Enterolactone and Prostate Cancer Risk (Sweden)." Cancer Causes & Control : CCC, vol. 15, no. 10, 2004, pp. 1095-102.
Stattin P, Bylund A, Biessy C, et al. Prospective study of plasma enterolactone and prostate cancer risk (Sweden). Cancer Causes Control. 2004;15(10):1095-102.
Stattin, P., Bylund, A., Biessy, C., Kaaks, R., Hallmans, G., & Adlercreutz, H. (2004). Prospective study of plasma enterolactone and prostate cancer risk (Sweden). Cancer Causes & Control : CCC, 15(10), 1095-102.
Stattin P, et al. Prospective Study of Plasma Enterolactone and Prostate Cancer Risk (Sweden). Cancer Causes Control. 2004;15(10):1095-102. PubMed PMID: 15801493.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prospective study of plasma enterolactone and prostate cancer risk (Sweden). AU - Stattin,Pär, AU - Bylund,Annika, AU - Biessy,Carine, AU - Kaaks,Rudolf, AU - Hallmans,Göran, AU - Adlercreutz,Herman, PY - 2005/4/2/pubmed PY - 2005/5/4/medline PY - 2005/4/2/entrez SP - 1095 EP - 102 JF - Cancer causes & control : CCC JO - Cancer Causes Control VL - 15 IS - 10 N2 - OBJECTIVES: Enterolactone, a phytoestrogen produced by the intestinal microflora from precursors in plant foods, has been postulated to protect against hormone-dependent cancers. We studied the association between plasma enterolactone and risk of prostate cancer. METHODS: In the Northern Sweden Health and Disease Cohort, enterolactone concentrations were measured by time-resolved fluoroimmunoassay in plasma taken from 265 men who were diagnosed with prostate cancer at a mean time of 5 years after blood collection, and in plasma from 525 control men, matched for age and date of blood collection. RESULTS: There was no significant association between quartiles of plasma enterolactone and risk of prostate cancer. Odds ratios for prostate cancer, estimated by conditional logistic regression for increasing concentrations of enterolactone in quartiles were 1.00 (referent), 0.81 (95% confidence interval 0.52-1.27), 1.03 (0.67-1.58), and 1.22 (0.80-1.86). Adjustments for body mass index (BMI), smoking status and stratification for age, lag time, storage time and tumour characteristics did not materially alter risk estimates. Men with very low enterolactone levels, however, had significantly higher risk of prostate cancer, odds ratio for bottom decile versus all other deciles was 1.68 (1.03-2.74). CONCLUSIONS: Our results do not support the hypothesis that enterolactone formed from dietary lignans protects against prostate cancer. SN - 0957-5243 UR - https://www.unboundmedicine.com/medline/citation/15801493/Prospective_study_of_plasma_enterolactone_and_prostate_cancer_risk__Sweden__ L2 - http://www.diseaseinfosearch.org/result/9175 DB - PRIME DP - Unbound Medicine ER -